Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-03-26

Last Posted Date: 2018-08-17

Lead Sponsor: Montefiore Medical Center

Target Recruit Count: 35

Registration Number: NCT00002461

Locations: 🇺🇸
Albert Einstein Comprehensive Cancer Center, Bronx, New York, United States

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-03-26

Last Posted Date: 2015-01-14

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT00002592

Locations: 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States

Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myeloid Leukemia

Phase 3

Completed

Conditions: Leukemia

First Posted Date: 2004-03-19

Last Posted Date: 2010-03-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 100

Registration Number: NCT00002789

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Phase 3

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: filgrastim
Drug: cisplatin
Drug: cyclophosphamide
Drug: dexamethasone
Drug: etoposide
Drug: thalidomide

First Posted Date: 2004-03-16

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 19

Registration Number: NCT00005834

Locations: 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States

and more 90 locations

S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Myelodysplastic Syndromes
Leukemia

Interventions: Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methotrexate
Procedure: allogeneic bone marrow transplantation
Radiation: radiation therapy

First Posted Date: 2004-03-16

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 240

Registration Number: NCT00005866

Locations: 🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
CCOP - Virginia Mason Research Center, Seattle, Washington, United States
🇺🇸
St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

and more 63 locations

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Small Cell Lung Cancer

Phase 3

Conditions: Lung Cancer

First Posted Date: 2004-03-12

Last Posted Date: 2009-02-09

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 280

Registration Number: NCT00002858

Locations: 🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Hopital Haut Leveque, Pessac, France
🇫🇷
CHRU de Nancy - Hopitaux de Brabois, Vandoeuvre-Les-Nancy, France

and more 16 locations

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-03-11

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 1000

Registration Number: NCT00002580

Locations: 🇬🇧
University Hospitals of Leicester, Leicester, England, United Kingdom
🇬🇧
Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom
🇬🇧
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom

and more 7 locations

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

First Posted Date: 2004-03-11

Last Posted Date: 2013-11-06

Lead Sponsor: Scottish Cancer Therapy Network

Target Recruit Count: 1000

Registration Number: NCT00002581

Locations: 🇬🇧
Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom
🇬🇧
Beatson Oncology Centre, Glasgow, Scotland, United Kingdom
🇬🇧
Ayr Hospital, Ayr, United Kingdom

and more 6 locations

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma
Small Intestine Cancer

First Posted Date: 2004-03-10

Last Posted Date: 2012-09-24

Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Target Recruit Count: 25

Registration Number: NCT00079261

Locations: 🇭🇷
University Hospital Rebro, Zagreb, Croatia
🇳🇱
Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen, Netherlands
🇧🇪
Algemeen Ziekenhuis Sint-Augustinus, Wilrijk, Belgium

and more 3 locations

Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Peptide Vaccine Plus Montanide ISA-51, and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-03-10

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00079144

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy